Casma Therapeutics to Present at Stifel 2022 Healthcare Conference

November 8, 2022

CAMBRIDGE, Mass., November 8, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the Stifel 2022 Healthcare Conference on Wednesday November 16,, 2022 at 3:00pm ET in New York, NY.

About Casma Therapeutics, Inc.
Casma Therapeutics, Inc. is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery targets large and complex disease targets such as organelles, protein aggregates and large signaling complexes and before directing them to the lysosome for elimination. By selectively degrading disease targets by autophagy, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders. For more information, please visit Casma’s new website, www.casmatx.com.

Contact
Colleen DeSimone
SVP, Finance
cdesimone@casmatx.com
857-777-4990

Back to news & media

Keep reading:

News June 5, 2025
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]
News April 17, 2024
Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]